tetano
Editor, Senior Moderator
mBio
. 2024 Jul 22:e0180424.
doi: 10.1128/mbio.01804-24. Online ahead of print. Exploiting the Affimer platform against influenza A virus
Oliver Debski-Antoniak[SUP] 1 2 [/SUP], Alex Flynn[SUP] #[/SUP][SUP] 2 3 [/SUP], David P Klebl[SUP] #[/SUP][SUP] 2 3 [/SUP], Moisés H Rojas Rechy[SUP] #[/SUP][SUP] 1 2 [/SUP], Christian Tiede[SUP] 1 2 [/SUP], Ian A Wilson[SUP] 4 [/SUP], Stephen P Muench[SUP] 2 3 [/SUP], Darren Tomlinson[SUP] 1 2 [/SUP], Juan Fontana[SUP] 1 2 [/SUP]
Affiliations
Influenza A virus (IAV) is well known for its pandemic potential. While current surveillance and vaccination strategies are highly effective, therapeutic approaches are often short-lived due to the high mutation rates of IAV. Recently, monoclonal antibodies (mAbs) have emerged as a promising therapeutic approach, both against current strains and future IAV pandemics. In addition to mAbs, several antibody-like alternatives exist, which aim to improve upon mAbs. Among these, Affimers stand out for their short development time, high expression levels in Escherichia coli, and animal-free production. In this study, we utilized the Affimer platform to isolate and produce specific and potent inhibitors of IAV. Using a monomeric version of the IAV trimeric hemagglutinin (HA) fusion protein, we isolated 12 Affimers that inhibit IAV infection in vitro. Two of these Affimers were characterized in detail and exhibited nanomolar-binding affinities to the target H3 HA protein, specifically binding to the HA1 head domain. Cryo-electron microscopy (cryo-EM), employing a novel spray approach to prepare cryo-grids, allowed us to image HA-Affimer complexes. Combined with functional assays, we determined that these Affimers inhibit IAV by blocking the interaction of HA with the host-cell receptor, sialic acid. Furthermore, these Affimers inhibited IAV strains closely related to the one used for their isolation. Overall, our results support the use of Affimers as a viable alternative to existing targeted therapies for IAV and highlight their potential as diagnostic reagents.
Importance: Influenza A virus is one of the few viruses that can cause devastating pandemics. Due to the high mutation rates of this virus, annual vaccination is required, and antivirals are short-lived. Monoclonal antibodies present a promising approach to tackle influenza virus infections but are associated with some limitations. To improve on this strategy, we explored the Affimer platform, which are antibody-like proteins made in bacteria. By performing phage-display against a monomeric version of influenza virus fusion protein, an established viral target, we were able to isolate Affimers that inhibit influenza virus infection in vitro. We characterized the mechanism of inhibition of the Affimers by using assays targeting different stages of the viral replication cycle. We additionally characterized HA-Affimer complex structure, using a novel approach to prepare samples for cryo-electron microscopy. Overall, these results show that Affimers are a promising tool against influenza virus infection.
Keywords: Affimer; cryo-electron microscopy sample preparation; influenza A virus; mAb.
. 2024 Jul 22:e0180424.
doi: 10.1128/mbio.01804-24. Online ahead of print. Exploiting the Affimer platform against influenza A virus
Oliver Debski-Antoniak[SUP] 1 2 [/SUP], Alex Flynn[SUP] #[/SUP][SUP] 2 3 [/SUP], David P Klebl[SUP] #[/SUP][SUP] 2 3 [/SUP], Moisés H Rojas Rechy[SUP] #[/SUP][SUP] 1 2 [/SUP], Christian Tiede[SUP] 1 2 [/SUP], Ian A Wilson[SUP] 4 [/SUP], Stephen P Muench[SUP] 2 3 [/SUP], Darren Tomlinson[SUP] 1 2 [/SUP], Juan Fontana[SUP] 1 2 [/SUP]
Affiliations
- PMID: 39037231
- DOI: 10.1128/mbio.01804-24
Influenza A virus (IAV) is well known for its pandemic potential. While current surveillance and vaccination strategies are highly effective, therapeutic approaches are often short-lived due to the high mutation rates of IAV. Recently, monoclonal antibodies (mAbs) have emerged as a promising therapeutic approach, both against current strains and future IAV pandemics. In addition to mAbs, several antibody-like alternatives exist, which aim to improve upon mAbs. Among these, Affimers stand out for their short development time, high expression levels in Escherichia coli, and animal-free production. In this study, we utilized the Affimer platform to isolate and produce specific and potent inhibitors of IAV. Using a monomeric version of the IAV trimeric hemagglutinin (HA) fusion protein, we isolated 12 Affimers that inhibit IAV infection in vitro. Two of these Affimers were characterized in detail and exhibited nanomolar-binding affinities to the target H3 HA protein, specifically binding to the HA1 head domain. Cryo-electron microscopy (cryo-EM), employing a novel spray approach to prepare cryo-grids, allowed us to image HA-Affimer complexes. Combined with functional assays, we determined that these Affimers inhibit IAV by blocking the interaction of HA with the host-cell receptor, sialic acid. Furthermore, these Affimers inhibited IAV strains closely related to the one used for their isolation. Overall, our results support the use of Affimers as a viable alternative to existing targeted therapies for IAV and highlight their potential as diagnostic reagents.
Importance: Influenza A virus is one of the few viruses that can cause devastating pandemics. Due to the high mutation rates of this virus, annual vaccination is required, and antivirals are short-lived. Monoclonal antibodies present a promising approach to tackle influenza virus infections but are associated with some limitations. To improve on this strategy, we explored the Affimer platform, which are antibody-like proteins made in bacteria. By performing phage-display against a monomeric version of influenza virus fusion protein, an established viral target, we were able to isolate Affimers that inhibit influenza virus infection in vitro. We characterized the mechanism of inhibition of the Affimers by using assays targeting different stages of the viral replication cycle. We additionally characterized HA-Affimer complex structure, using a novel approach to prepare samples for cryo-electron microscopy. Overall, these results show that Affimers are a promising tool against influenza virus infection.
Keywords: Affimer; cryo-electron microscopy sample preparation; influenza A virus; mAb.